Copyright 2002 American Medical Association. All Rights Reserved.
Applicable FARS/DFARS Restrictions Apply to Government Use.2002
We thank Dr Hesse for his insightful comments. In our study, the supplier
of tPA was Genentech Inc, San Francisco, Calif (the commercial name is Activase),
and the tPA was diluted in sterile balanced salt solution (Alcon Laboratories,
Ft Worth, Tex). A 30-gauge needle on a tuberculin syringe was used to inject
a 0.1 to 0.2 mL dose of tPA. The concentration of tPA was either 20 µg/mL
or 30 µg/mL, depending on the physician who ordered the tPA. The dose
recorded in the table represents what the physician estimated to be the true
dose injected into the vitreous.
Blodi B. Treating Subretinal Hemorrhage With Tissue Plasminogen Activator. Arch Ophthalmol. 2002;120(1):103. doi: